LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -4.03% | -0.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.03% | -0.81% | |||
| Cost of Revenue | 6.37% | -13.29% | |||
| Gross Profit | -22.01% | 32.06% | |||
| SG&A Expenses | -35.73% | 70.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.17% | 7.16% | |||
| Operating Income | 160.79% | -178.16% | |||
| Income Before Tax | 24.95% | -81.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.95% | -81.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.95% | -81.56% | |||
| EBIT | 160.79% | -178.16% | |||
| EBITDA | 116.36% | -60.81% | |||
| EPS Basic | 30.56% | -44.00% | |||
| Normalized Basic EPS | 33.33% | -60.00% | |||
| EPS Diluted | 30.56% | -44.00% | |||
| Normalized Diluted EPS | 33.33% | -60.00% | |||
| Average Basic Shares Outstanding | 8.80% | 25.06% | |||
| Average Diluted Shares Outstanding | 8.86% | 25.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
